Search

“Prolonged Clonazepam-Induced Withdrawal Symptoms in an NAT2 Ultraslow Acetylator. Pharmacogenomics, 20(2), 69–73. Https://Doi.org/10.2217/Pgs-2018-0145”. 2019. Journal of Iaculis Nisl Facilisis Malesuada Maecenas.

“Results from a 78-Week, Single-Arm, Open-Label Phase 2 Study to Evaluate UX007 in Pediatric and Adult Patients With Severe Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD). Journal of Inherited Metabolic Disease, 42(1), 169–177.”. 2019. Journal of Inherited Metabolic Disease.

Pahwa, R, S Fox, RA Hauser, S Isaacson, J Lytle, R Johnson, L Llorens, AE Formella, and CM Tanner. 2022. “Clinically Important Change on the Unified Dyskinesia Rating Scale Among Patients With Parkinson’s Disease Experiencing Dyskinesia. 2022 Oct 20;13:846126. Doi: 10.3389/Fneur.2022.846126. ECollection 2022. PMID: 36341088”. Front Neurol.

Soileau, MJ, J Aldred, K Budur, N Fisseha, VS Fung, A Jeong, TE Kimber, et al. 2022. “Safety and Efficacy of Continuous Subcutaneous Foslevodopa-Foscarbidopa in Patients With Advanced Parkinson’s Disease: a Randomised, Double-Blind, Active-Controlled, Phase 3 Trial. 2022 Dec;21(12):1099-1109. Doi: 10. PMID: 36402160”. Lancet Neurol.

Simuni, T, B Fiske, K Merchant, CS Coffey, E Klingner, C Caspell-Garcia, DE Lafontant, et al. 2021. “Parkinson Study Group NILO-PD Investigators and Collaborators (including Hauser RA). Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol 2021;78:312-320.”. JAMA Neurol.

Doiron, Jake E, Mahmoud H Elbatreek, Huijing Xia, Xiaoman Yu, W H Wilson Tang, Kyle B LaPenna, Thomas E Sharp, et al. 2024. “Reduced Hydrogen Sulfide Bioavailability Contributes to Cardiometabolic Heart Failure With Preserved Ejection Fraction.”. BioRxiv : The Preprint Server for Biology.

Naito, A, AM Wills, TF Tropea, A Ramirez-Zamora, RA Hauser, D Martino, TH Turner, and . 2021. “Expediting Telehealth Use in Clinical Research Studies: Recommendations for Overcoming Barriers in North America. NPJ Parkinsons Dis 2021;7:34. Doi: 10.1038/S41531-021-00177-8.PMID: 33846349”. NP J Parkinsons Dis.

Mehta, SH, R Pahwa, CM Tanner, RA Hauser, and R Johnson. 2021. “Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients With Parkinson’s Disease and Dyskinesia. Neurol Ther. 2021 Jun;10(1):307-320. Doi: 10.1007/S40120-021-00246-3”. Neurol Ther.

Videnovic, A, AW Amara, C Comella, PK Schweitzer, H Emsellem, K Liu, AL Sterkel, et al. 2021. “Solriamfetol for Excessive Daytime Sleepiness in Parkinson’s Disease: Phase 2 Proof-of-Concept Trial. Mov Disord. 2021 Oct;36(10):2408-2412. Doi: 10.1002/Mds.28702. Epub 2021 Jun 30. PMID: 34191352.”. Mov Disord.